ImmunityBio Finally Settled $10.5M With Investors Over Drug Release Issues

Hey guys, any IBRX investors here? If you missed it, we finally got some news about Anktiva's development and approval issues they had a few years ago. For newbies, back in 2021, ImmunityBio promoted Anktiva as a breakthrough treatment, with a high chance of getting FDA approval. But, two years later, the company announced that the FDA rejected this new drug over production deficiencies. This news led $IBRX to drop over 55% and to a lawsuit from investors for the losses.  And now, ImmunityBio finally decided to settle and pay $10.5M to shareholders to resolve the whole situation. So if you were damaged back then you can check the info and [file for payment here](https://11thestate.com/cases/immunitybio-investor-case) or through the settlement admin. Anyways, anyone here bought $IBRX back then? How much were your losses if so?